Featured Tickers:
Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Ultragenyx Pharmaceutical Inc. or Aurinia Pharmaceuticals Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.
Read on to learn how Ultragenyx Pharmaceutical Inc. and Aurinia Pharmaceuticals Inc. compare based on key financial metrics to determine which better meets your investment needs.
About Ultragenyx Pharmaceutical Inc. and Aurinia Pharmaceuticals Inc.
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company’s products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome. It also develops UX701 that is in Phase 2 clinical trial for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Solid Biosciences Inc.; Regeneron; Abeona; and Arcturus Therapeutics Holdings Inc. The company was incorporated in 2010 and is headquartered in Novato, California.
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs. It offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. The company also develops AUR200, a dual inhibitor of B cell activating factor and a proliferation inducing ligand for the potential treatment of autoimmune diseases. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
Latest Biotechnology and Ultragenyx Pharmaceutical Inc., Aurinia Pharmaceuticals Inc. Stock News
As of November 21, 2025, Ultragenyx Pharmaceutical Inc. had a $3.2 billion market capitalization, compared to the Biotechnology median of $197.3 million. Ultragenyx Pharmaceutical Inc.’s stock is down 20.2% in 2025, up 1.5% in the previous five trading days and down 25.57% in the past year.
Currently, Ultragenyx Pharmaceutical Inc. does not have a price-earnings ratio. Ultragenyx Pharmaceutical Inc.’s trailing 12-month revenue is $630.6 million with a -91.9% net profit margin. Year-over-year quarterly sales growth most recently was 14.6%. Analysts expect adjusted earnings to reach $-5.772 per share for the current fiscal year. Ultragenyx Pharmaceutical Inc. does not currently pay a dividend.
As of November 21, 2025, Aurinia Pharmaceuticals Inc. had a $2.1 billion market cap, putting it in the 57th percentile of all stocks. Aurinia Pharmaceuticals Inc.’s stock is up 74.6% in 2025, up 2.1% in the previous five trading days and up 92.87% in the past year.
Currently, Aurinia Pharmaceuticals Inc.’s price-earnings ratio is 28.5. Aurinia Pharmaceuticals Inc.’s trailing 12-month revenue is $265.8 million with a 29.3% net profit margin. Year-over-year quarterly sales growth most recently was 8.4%. Analysts expect adjusted earnings to reach $0.782 per share for the current fiscal year. Aurinia Pharmaceuticals Inc. does not currently pay a dividend.
How We Compare Ultragenyx Pharmaceutical Inc. and Aurinia Pharmaceuticals Inc. Stock Grades
Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.
AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Ultragenyx Pharmaceutical Inc. and Aurinia Pharmaceuticals Inc.’s stock grades to see how they measure up against one another.
Learn more about A+ Investor here!
Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions